Clinical Trial Update: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating DFP-10917 versus non-intensive or intensive reinduction for acute myeloid leukemia in 2nd to 4th salvage was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• DFP-10917

Snippet

Sponsor: Delta-Fly Pharma, Inc. | Conditions: Leukemia, Myeloid, Acute | Phase 3 | Status: TERMINATED